Conceptual map for pharma AI visibility across brands, markets and therapeutic categories
Life Sciences Insights

How Pharma Companies Should Measure AI Visibility Across Brands, Countries and Therapeutic Categories

Measure pharma AI visibility as a set of market-specific observations, not one company-wide score. Separate corporate and product brands, countries and languages, therapeutic categories, and professional versus patient audiences. For each question, record whether the intended entity appears, whether the answer is accurate, which sources support it, and what action follows.

A parent-brand mention should not authorize a product campaign. The operating constraint is whether the relevant local evidence and review owner support that next step. Here, visibility means observed presence in AI-generated answers—not clinical validity, market authorization, purchasing intent or revenue.

Define the decision before counting the mentions

Start with the executive question: which brand, in which market, needs to be understood by which audience? A corporate reputation audit, a patient-information review and a manufacturing-partner shortlist require different questions and different reviewers. Do not combine them merely because the same parent company appears.

For pharma AI visibility, keep these signals separate:

  • Mention: the intended entity appears in the answer.
  • Factual alignment: the statements about that entity match the applicable reference material.
  • Citation: the answer links to a source that can be inspected.
  • Recommendation: the answer explicitly presents the entity as an option for the stated task.
  • Next-step fit: the destination and contact route suit the audience and market.

Count a citation as a citation, not as an endorsement. Record paid placements separately from organic answers and source links. Do not use an AI-generated answer as evidence of treatment safety, efficacy or individual suitability.

Make this segmentation part of the wider life sciences marketing plan. Otherwise, the measurement team may optimize for a mention that the local commercial or medical team cannot use.

Build a bounded pilot across markets, brands and questions

Use a small, explicit sample before commissioning a global dashboard. One proposed starting design is 30 localized questions: ten in each of three selected markets. These are planning quantities, not a benchmark for adequate coverage.

Choose the markets because a decision depends on them: a portfolio review, a local information gap or a supplier-development priority. Within each market, map corporate names, relevant subbrands, language variants and the therapeutic or capability category being evaluated.

Then assign each question to a specific audience and task. Useful question families include:

  • Corporate discovery: which company owns or operates a named brand?
  • Category discovery: which organizations are associated with the defined therapeutic area or manufacturing capability?
  • Source finding: where can the user find the applicable official information?
  • Professional information: which source addresses the stated HCP information need?
  • Supplier evaluation: what evidence should a procurement team request about a stated capability?

Write local questions with a local reviewer rather than treating translation as sufficient. Preserve the same underlying task where comparison is intended, but retain meaningful differences in terminology and audience.

Make the collection workload visible

For illustration, 30 questions across two answer surfaces and three capture waves create 180 planned observations: 30 × 2 × 3. That is a collection workload, not 180 people reached, independent users or purchase opportunities.

Define an observation as one question, on one surface, under recorded conditions, at one capture time. Assign a stable question ID and record the interface or model identifier when available. Keep a question introduced during the pilot out of the original baseline comparison unless the baseline is rebuilt.

Do not place patient data, confidential trial information or private commercial records into public prompts. Use the public, audience-appropriate questions the pilot is designed to assess.

The Percepture Market–Brand–Evidence scorecard

This guide proposes a five-gate operating worksheet for pharma AI visibility. Its purpose is to turn an observation into an owned decision—not to grade clinical evidence or certify regulatory compliance.

  1. Discovery: did the intended entity appear?

    Record the exact name used, the parent–subbrand relationship and any ambiguity. Keep a competitor mention, a parent-company mention and the intended product-brand mention in separate fields. Assign entity corrections to the brand or portfolio owner.

  2. Targeting: does the answer fit the market and audience?

    Check country, language, therapeutic category and intended reader. Have the appropriate local owner assess the jurisdiction and audience fit. Do not let an answer intended for a professional audience stand in for a patient-facing assessment.

  3. Factual alignment: what does the answer actually say?

    Extract the material statements about ownership, capabilities, availability or other relevant attributes. Ask the responsible subject-matter reviewer to compare those statements with the applicable reference material. Mark unresolved statements for review rather than assigning them a favorable score.

  4. Evidence: can the source be traced?

    Retain the cited URL, the supporting passage and the source’s applicable market or scope. For medical statements, use the organization’s designated medical-review process. A recognizable source name alone is not the review result.

  5. Delivery: is there an appropriate next step?

    Inspect the destination page, audience controls where applicable, and the route to the responsible team. For a supplier inquiry, include capability fit, delivery constraints and the commercial owner. Do not hand an information-seeking patient question into a sales workflow.

Use pass, review, fail or not applicable at each gate, with a short reason and an owner. Preserve the individual gate results. Do not average an unresolved medical statement into an attractive overall score.

The decision worksheet

For each priority issue, complete one line: question ID → market and audience → observed problem → reference material → responsible owner → proposed correction → next comparable capture. Add the brand relationship and intended destination when they affect the decision.

That line is the handoff. If nobody can own the correction, keep the issue in the work queue rather than treating it as an optimization completed.

Which measurement scope fits the decision?

Choose the scope by the decision it must support. The following are proposed audit designs, not vendor rankings or results from a comparative test.

Measurement scopes, tradeoffs and recommended uses
ScopeResponsible teamEvidence or metricWrong interpretationDrawbackRecommended action
Corporate-brand overviewCorporate marketing and communicationsEntity recognition and ownership accuracyParent visibility proves product visibilityLimited detail about local brandsUse for reputation questions; inspect subbrands separately
Therapeutic-category deep divePortfolio marketing with medical reviewersCategory inclusion, statement accuracy and source fitBeing named establishes treatment superiorityRequires narrowly defined questions and review expertiseChoose a category with a specific portfolio decision
Country-and-language auditLocal marketing and regulatory ownersLocal entity accuracy and applicable source coverageOne language represents every market using itLocalization and review add workStart with markets that have an accountable local owner
HCP and patient journey auditMedical, channel and patient-information teamsAudience fit and appropriate information destinationsThe same answer and CTA suit both audiencesRequires separate question sets and escalation routesReport professional and patient-facing cohorts separately
Supplier or CDMO buying auditBusiness development, technical and quality teamsCapability representation and qualified inquiry routingA shortlist mention proves capacity or contract suitabilityRequires operational evidence beyond marketing copyConnect findings to CDMO business development strategy

A corporate scan can be a sensible first boundary check. The objection is not that it lacks value; it is that its result should not answer a more specific product, clinical-information or procurement question.

Report coverage with denominators, not a floating score

For pharma AI visibility reporting, show the question set, observation count and review status beside every percentage. Keep the answer surfaces separate. A pooled total should not obscure which market or interface supplied the observations.

Use clearly defined measures:

  • Observed mention coverage: eligible responses naming the intended entity divided by all valid eligible responses in that cohort.
  • Source-supported coverage: eligible responses with a reviewed, applicable source supporting the relevant statement divided by all valid eligible responses.
  • Audience-fit coverage: eligible responses meeting the agreed audience and market checks divided by all valid eligible responses.
  • Unresolved issues: the raw count of observations still awaiting the designated reviewer.

As a hypothetical arithmetic example, 12 mentions among 30 valid responses equal 40% observed mention coverage. If only nine meet the agreed source and audience checks, report nine of 30, or 30%, for that combined measure. Neither percentage describes population reach or clinical correctness.

Log failed captures and unavailable answers separately from valid answers that omit the brand. Publish the collection-completion count alongside the results so technical failures do not disappear from the denominator.

A repeatable observation method

Save the exact prompt, capture date, surface, available configuration details, response text, cited URLs and reviewer decisions. Record settings where observable; do not guess about hidden conditions. Use a stable baseline question set, and label exploratory follow-up questions separately.

When comparing waves, identify changes to the website, reference material and collection method. Treat an observed movement as a finding to investigate, not proof that a particular intervention caused it. For the broader reporting structure, use the companion guide to measure GEO campaign success.

Budget for review and correction—not just collection

Scope the work before comparing prices. Ask for separate estimates for question design, localization, collection, factual review, technical investigation, content correction and reporting. Include internal reviewer time in the resource plan, even when it does not appear on an agency invoice.

A practical budgeting worksheet is: collection workload + reviewer workload + correction backlog + reporting and governance. Estimate each component against an owner and an agreed deliverable. Do not turn that worksheet into a cost forecast until the team has supplied its rates and effort assumptions.

If buying software, ask the provider to show how it exports raw observations, preserves question versions, distinguishes capture failures and records source links. Confirm language, market and surface coverage against your own pilot requirements. Do not infer those capabilities from a dashboard label.

If buying managed services, clarify who resolves disputed statements and who can approve a local content change. Require a sample deliverable that separates observations, reviewer judgments and recommended actions. The useful comparison is the work included—not simply the number of prompts advertised.

Turn a finding into the right kind of work

Do not respond to every absence by publishing another article. Diagnose the failed gate first. A naming problem calls for entity clarification. A missing local reference calls for source work. An inappropriate destination calls for a journey correction. A disputed medical statement belongs with the designated medical owner.

Use the following sequence to connect the measurement work to delivery:

  • Earned authority: use digital PR services to support substantiated, audience-relevant communications—not to manufacture evidence.
  • Owned discovery: maintain clear brand relationships, accessible reference pages and deliberate internal links. Use Google’s AI features documentation as the platform reference for the Google Search portion of the audit.
  • Answer evaluation: connect the observation and correction cycle to the work scoped under generative engine optimization services.
  • Distribution and follow-up: coordinate owned and paid channels through an omnichannel marketing plan, retaining audience boundaries and permission requirements.
  • Conversion and handoff: send appropriate commercial inquiries to the responsible team; keep medical-information requests on their designated route.

Measure downstream activity separately. A source click, an inquiry, an accepted opportunity and a closed contract are different events. Preserve that distinction when presenting results to the CFO.

What should happen after the pilot?

Expand only when the team can explain the findings and act on them. Keep the baseline questions, add a clearly labeled expansion cohort, and reassess the review workload. Do not assume that a stronger result in one market predicts the result in another.

Tomorrow, name an executive sponsor, a measurement owner and the relevant local reviewers. Select the first markets or categories, draft the question inventory, and agree on the reference material before collection begins. The first deliverable should be an owned visibility map and correction queue—not a global score with no decision attached.

Questions about running the pilot

Should we begin with the parent company or individual brands?

Begin with the entity tied to the decision. Use a parent-company cohort for corporate reputation and ownership questions. Use separate brand cohorts when the decision concerns a particular product, market or information journey.

Is a 30-question pilot enough?

Use it as a bounded starting design, not a statistical guarantee. Check whether it covers the decisions, audiences and markets in scope. Add questions when they address a material gap, and label the expanded cohort separately.

Should HCP and patient-facing answers share a score?

Keep them separate. Give each audience its own question set, reference material, review owner and destination checks. An executive summary can show both cohorts without combining their results.

How often should we repeat the measurements?

Choose a cadence that matches the decision and available review capacity. Retain scheduled baseline captures, and add clearly labeled checks after relevant source or website changes. Avoid making budget decisions from a single observation.

Can one AI citation demonstrate return on investment?

No. Record the citation as an observed source link. Assess referrals, appropriate inquiries, accepted opportunities and revenue separately, using an attribution method suited to the business. Do not claim causation from the citation alone.

Who should review potentially inaccurate medical statements?

Route them through the organization’s designated medical and regulatory review process. Marketing should preserve the observation and supporting sources, assign an owner and avoid treating an unresolved statement as acceptable.

What should an AI visibility vendor demonstrate?

Ask for raw observation exports, stable question IDs, collection conditions, failure handling, source traceability and a clear review workflow. Confirm the specific markets, languages and surfaces included in the proposed scope.

What should the first management report contain?

Show the pilot boundary, valid and failed capture counts, separate cohort measures, unresolved issues and the correction queue. End with the decisions required, their owners and the next comparable measurement point.

Bob Generale, President of Percepture

About Bob Generale

Bob Generale is President of Percepture. This guide presents a marketing measurement and operating perspective, not clinical or legal advice.

Meet the Percepture team